1. Home
  2. TYGO vs NGNE Comparison

TYGO vs NGNE Comparison

Compare TYGO & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tigo Energy Inc.

TYGO

Tigo Energy Inc.

HOLD

Current Price

$4.80

Market Cap

380.1M

Sector

Technology

ML Signal

HOLD

Logo Neurogene Inc.

NGNE

Neurogene Inc.

HOLD

Current Price

$26.95

Market Cap

327.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TYGO
NGNE
Founded
2007
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
380.1M
327.8M
IPO Year
2021
2014

Fundamental Metrics

Financial Performance
Metric
TYGO
NGNE
Price
$4.80
$26.95
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
7
Target Price
$6.00
$63.57
AVG Volume (30 Days)
537.1K
151.1K
Earning Date
05-05-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
97.12
0.93
EPS
N/A
N/A
Revenue
$103,536,000.00
N/A
Revenue This Year
$30.78
N/A
Revenue Next Year
$21.68
N/A
P/E Ratio
N/A
N/A
Revenue Growth
91.68
N/A
52 Week Low
$0.81
$11.78
52 Week High
$5.33
$37.27

Technical Indicators

Market Signals
Indicator
TYGO
NGNE
Relative Strength Index (RSI) 59.79 61.81
Support Level $3.24 $19.40
Resistance Level N/A $29.05
Average True Range (ATR) 0.46 1.99
MACD 0.05 0.05
Stochastic Oscillator 68.85 78.42

Price Performance

Historical Comparison
TYGO
NGNE

About TYGO Tigo Energy Inc.

Tigo Energy Inc provides solar and energy storage solutions, including module level power electronics (MLPE) designed to maximize the energy output of individual solar modules, delivering more energy, active management, and enhanced safety for utility, commercial, and residential solar arrays. By combining its MLPE and solar optimizer technology with intelligent, cloud-based software capabilities, the Company enables developed energy monitoring, system diagnostics, and real-time control. Geographically the company generates revenue from EMEA, Americas, and APAC.

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

Share on Social Networks: